Tumor weight measurements revealed a marked reduction in tumor burden in both the Bcl9@TP alone group and combination (Bcl9@TP + anti-PD-1) group compared to the control and anti-PD-1 groups, with the combination group exhibiting the most pronounced effect—an approximate 85% decrease in tumor mass (Figure 4C). Here, BCL9 is linked to neoplasm.